Veronika Fedirko, Talita Duarte‐Salles, Christina Bamia, Antonia Trichopoulou, Krasimira Aleksandrova, Dimitrios Trichopoulos, Elisabeth Trepo, Anne Tjønneland, Anja Olsen, Kim Overvad, Marie‐Christine Boutron‐Ruault, Françoise Clavel‐Chapelon, Marina Kvaskoff, Tilman Kühn, Annie Lukanova, Heiner Boeing, Brian Buijsse, Eleni Klinaki, Chrysanthi Tsimakidi, Alessio Naccarati, Giovanna Tagliabue, Salvatore Panico, Rosario Tumino, Domenico Palli, H. Bas Bueno‐de‐Mesquita, Peter D. Siersema, Petra H.

Brett E. Fortune, Roberto J. Groszmann – 20 February 2014

Jessica Liu, Hwai‐I Yang, Mei‐Hsuan Lee, Richard Batrla‐Utermann, Chin‐Lan Jen, Sheng‐Nan Lu, Li‐Yu Wang, San‐Lin You, Chuhsing Kate Hsiao, Chien‐Jen Chen, the R.E.V.E.A.L.‐HBV Study Group – 20 February 2014 – Spontaneous seroclearance of hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV) DNA undetectability are important milestones of chronic hepatitis B and major treatment endpoints of antiviral therapy. This study investigated the role of serum hepatitis B surface antigen (HBsAg) levels and established models for predicting HBeAg seroclearance and HBV DNA undetectability.

Jing Yang, Laura E. Mowry, Kari Nichole Nejak‐Bowen, Hirohisa Okabe, Cassandra R. Diegel, Richard A. Lang, Bart O. Williams, Satdarshan P. Monga – 20 February 2014 – Liver‐specific β‐catenin knockout (β‐Catenin‐LKO) mice have revealed an essential role of β‐catenin in metabolic zonation where it regulates pericentral gene expression and in initiating liver regeneration (LR) after partial hepatectomy (PH), by regulating expression of Cyclin‐D1. However, what regulates β‐catenin activity in these events remains an enigma.

Jasmohan S. Bajaj, Jacqueline G. O'Leary, K. Rajender Reddy, Florence Wong, Scott W. Biggins, Heather Patton, Michael B. Fallon, Guadalupe Garcia‐Tsao, Benedict Maliakkal, Raza Malik, Ram M. Subramanian, Leroy R. Thacker, Patrick S. Kamath, the North American Consortium for the Study of End-stage Liver Disease (NACSELD) – 20 February 2014 – Infections worsen survival in cirrhosis; however, simple predictors of survival in infection‐related acute‐on‐chronic liver failure (I‐ACLF) derived from multicenter studies are required in order to improve prognostication and resource allocation.

Michael Bauer, Michael Kiehntopf – 20 February 2014

Jesper M. Kivelä, Silja Kosola, Teija Kalajoki‐Helmiö, Heikki Mäkisalo, Hannu Jalanko, Christer Holmberg, Mikko P. Pakarinen, Jouni Lauronen – 18 February 2014 – Hepatic artery thrombosis (HAT) after liver transplantation (LT) increases patient morbidity and mortality. Early HAT is considered to occur within the first month after LT, whereas late HAT occurs after the first month. Few studies have addressed late HAT after LT, especially in pediatric patients. Between 1987 and 2007, 99 patients (age < 18 years) underwent deceased donor LT.

Jayant A. Talwalkar – 15 February 2014 – The Patient Protection and Affordable Care Act (ACA), along with the Health Care and Education Reconciliation Act, was signed into law and upheld by the Supreme Court earlier this year. The ACA contains a variety of reforms that, if implemented, will significantly affect current models of healthcare delivery for patients with acute and chronic hepatobiliary diseases.

Jayant A. Talwalkar – 15 February 2014 – The Patient Protection and Affordable Care Act (ACA), along with the Health Care and Education Reconciliation Act, was signed into law and upheld by the Supreme Court earlier this year. The ACA contains a variety of reforms that, if implemented, will significantly affect current models of healthcare delivery for patients with acute and chronic hepatobiliary diseases.

Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja‐Wyszomirska, Gideon M. Hirschfield, Olivier Barbier, Piotr Milkiewicz – 12 February 2014 – Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10‐15 mg/kg/day) were included.